170 related articles for article (PubMed ID: 28668757)
1. Determination of LongR
Thomas A; Walpurgis K; Delahaut P; Fichant E; Schänzer W; Thevis M
Growth Horm IGF Res; 2017 Aug; 35():33-39. PubMed ID: 28668757
[TBL] [Abstract][Full Text] [Related]
2. Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS.
Thomas A; Kohler M; Schänzer W; Delahaut P; Thevis M
Analyst; 2011 Mar; 136(5):1003-12. PubMed ID: 21157622
[TBL] [Abstract][Full Text] [Related]
3. Detection of LongR
Mongongu C; Coudoré F; Domergue V; Ericsson M; Buisson C; Marchand A
Drug Test Anal; 2021 Jul; 13(7):1256-1269. PubMed ID: 33587816
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
Thevis M; Thomas A; Geyer H; Schänzer W
Growth Horm IGF Res; 2014 Dec; 24(6):276-80. PubMed ID: 25466910
[TBL] [Abstract][Full Text] [Related]
5. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
Bredehöft M; Schänzer W; Thevis M
Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
[TBL] [Abstract][Full Text] [Related]
6. Detection of synthetic analogues of insulin-like growth factor 1 in different biological fluids by liquid chromatography quadrupole time-of-flight mass spectrometry: comparison of different immunoaffinity protocols.
Mazzarino M; Melis I; Quaresima E; Botrè F
Anal Bioanal Chem; 2023 Oct; 415(24):6117-6131. PubMed ID: 37566232
[TBL] [Abstract][Full Text] [Related]
7. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
Thomas A; Walpurgis K; Tretzel L; Brinkkötter P; Fichant E; Delahaut P; Schänzer W; Thevis M
Drug Test Anal; 2015; 7(11-12):990-8. PubMed ID: 26382721
[TBL] [Abstract][Full Text] [Related]
8. Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS).
Thomas A; Schänzer W; Thevis M
Drug Test Anal; 2014; 6(11-12):1125-32. PubMed ID: 25219675
[TBL] [Abstract][Full Text] [Related]
9. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
Thomas A; Schänzer W; Delahaut P; Thevis M
Methods; 2012 Feb; 56(2):230-5. PubMed ID: 21871962
[TBL] [Abstract][Full Text] [Related]
10. Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers.
Zvereva I; Dudko G; Dikunets M
Drug Test Anal; 2018 Apr; 10(4):711-722. PubMed ID: 28777889
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
[TBL] [Abstract][Full Text] [Related]
12. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.
Thomas A; Höppner S; Geyer H; Schänzer W; Petrou M; Kwiatkowska D; Pokrywka A; Thevis M
Anal Bioanal Chem; 2011 Aug; 401(2):507-16. PubMed ID: 21298258
[TBL] [Abstract][Full Text] [Related]
13. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
Gosetti F; Mazzucco E; Gennaro MC; Marengo E
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
[TBL] [Abstract][Full Text] [Related]
14. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
Knoop A; Thomas A; Fichant E; Delahaut P; Schänzer W; Thevis M
Anal Bioanal Chem; 2016 May; 408(12):3145-53. PubMed ID: 26879649
[TBL] [Abstract][Full Text] [Related]
15. Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry.
Görgens C; Guddat S; Thomas A; Wachsmuth P; Orlovius AK; Sigmund G; Thevis M; Schänzer W
J Pharm Biomed Anal; 2016 Nov; 131():482-496. PubMed ID: 27693991
[TBL] [Abstract][Full Text] [Related]
16. Capillary blood as a complementary matrix for doping control purposes. Application to the definition of the individual longitudinal profile of IGF-1.
Stacchini C; Botrè F; de la Torre X; Mazzarino M
J Pharm Biomed Anal; 2023 Apr; 227():115274. PubMed ID: 36774791
[TBL] [Abstract][Full Text] [Related]
17. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches.
Sigmund G; Koch A; Orlovius AK; Guddat S; Thomas A; Schänzer W; Thevis M
Drug Test Anal; 2014; 6(11-12):1197-205. PubMed ID: 24913825
[TBL] [Abstract][Full Text] [Related]
18. Insulin-mimetic peptides in sports drug testing.
Thomas A; Krombholz S; Breuer J; Walpurgis K; Thevis M
Drug Test Anal; 2023; 15(11-12):1468-1476. PubMed ID: 37691519
[TBL] [Abstract][Full Text] [Related]
19. Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry.
Thomas A; Kohler M; Schänzer W; Kamber M; Delahaut P; Thevis M
Rapid Commun Mass Spectrom; 2009 Sep; 23(17):2669-74. PubMed ID: 19630025
[TBL] [Abstract][Full Text] [Related]
20. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
